Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Adstiladrin Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.461

    Nadofaragene firadenovec-vncg (Adstiladrin) Coverage Policy

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.461 alerts

    Get alerted when Policy CP.PHAR.461 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Adstiladrin in adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer across commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerAmbetter Nevada
    PolicyNadofaragene firadenovec-vncg (Adstiladrin) Coverage Policy
    Policy CodePolicy CP.PHAR.461
    Change TypeModified
    Effective DateDecember 1, 2022
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with clinical records supporting that all applicable approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code J9029 was added for intravesical instillation of nadofaragene firadenovec-vncg per therapeutic dose.

    The initial approval criteria requirement for clinically significant elevated liver or renal function tests was removed.

    The policy was updated after Adstiladrin received FDA approval without significant changes to the approval criteria.

    The policy removed the initial-therapy requirement for clinically significant elevated liver or renal function tests.

    The policy added oncology dosing criteria permitting doses supported by practice guidelines or literature.

    The policy added an off-label indication for Ta/T1 high-grade disease without carcinoma in situ and added a requirement that the member not be a candidate for cystectomy.

    The policy removed the lifetime dose requirement, clarified that treatment frequency must not exceed every three months, and removed the specification that treatment consist of a single dose.

    The policy increased the initial and continued therapy approval duration to 12 months for this maintenance medication.

    HCPCS code J9029 was added as the referenced billing code for nadofaragene firadenovec-vncg intravesical instillation.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    BCG-unresponsive NMIBCCovered disease setting
    ≥18 yearsMinimum age
    12 monthsApproval duration
    75 mL / 4 vialsMaximum dose
    J9029Billing code

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following diagnoses

      • Carcinoma in situ (CIS) only.
      • Ta/T1 high-grade disease with concomitant CIS.
      • Ta/T1 high-grade disease without CIS (off-label).
    • Prescribed by or in consultation with an oncologist or urologist.
    • Member is age 18 years or older.>= 18 years
    • Member is refractory to BCG treatment.

      Prior authorization may be required for BCG immunotherapy.

    • Member is not a candidate for cystectomy.
    • If the request is for a dose increase, ONE of the following must apply

      • Dose does not exceed 75 mL (4 vials) of 3 x 10^11 viral particles (vp)/mL every 3 months.
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

        Prescriber must submit supporting evidence.

    Continuation Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Member is currently receiving the medication through the Centene benefit, or documentation supports that the member is currently receiving Adstiladrin for a covered indication and has received this medication for at least 30 days.
    • Member is responding positively to therapy, as evidenced by freedom from high-grade disease recurrence evaluated by cytology, cystoscopy, and/or biopsy.
    • If the request is for a dose increase, ONE of the following must apply

      • New dose does not exceed 75 mL (4 vials) of 3 x 10^11 vp/mL every 3 months.
      • New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

        Prescriber must submit supporting evidence.

    Other Diagnoses and Indications

    Covered when ONE of the following pathways applies:

    ONE of the following

    • Recently changed label not yet reflected in this policy

      • The drug has undergone a label change within the last 6 months, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
      • Formulary/PDL status determines the applicable policy

        • For drugs on the formulary (commercial or health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no-coverage-criteria policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • For drugs not on the formulary (commercial or health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy or evidence of coverage documents.

    The applicable off-label use policies for commercial, health insurance marketplace/ICHRA, and Medicaid are CP.CPA.09, HIM.PA.154, and CP.PMN.53, respectively. These policies or applicable evidence of coverage documents must support efficacy and safety for a non-FDA-approved indication not addressed in this policy.

    Adstiladrin is contraindicated in members with hypersensitivity to interferon alfa or any component of the product. There are no boxed warnings.

    Coding and Dosing Parameters

    Referenced HCPCS CodeHCPCS
    J9029Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
    Referenced HCPCS CodeHCPCS
    J9029Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
    Maximum Dose for Dose-Increase Requests
    Maximum volume75 mL
    Maximum quantity4 vials
    Concentration and frequency3 × 10^11 viral particles (vp)/mL every 3 months
    Standard High-Grade BCG-Unresponsive NMIBC Regimen
    Initial dose1 × 10^11 vp/mL or 3 × 10^11 vp/mL
    Retreatment scheduleRetreatment at months 4, 7, and 10
    Maximum course

    Prior Authorization and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Submit prior authorization with documentation showing that the member meets all applicable approval criteria for Adstiladrin.

    • Include clinical evidence supporting the requested indication, treatment status, dosing, and regimen.
    • The prescribed regimen must be FDA-approved or recommended by NCCN.
    Step Therapy

    Prior BCG Treatment Required

    Document that the member is refractory to or BCG-unresponsive following adequate prior BCG treatment.

    • Adequate BCG includes at least 5 of 6 induction doses plus either at least 2 of 3 maintenance doses or at least 2 of 6 doses in a second induction course.
    • Qualifying BCG-unresponsive status also includes recurrent high-grade Ta/T1 disease within 6 months after adequate BCG or T1 high-grade disease at the first evaluation after an induction BCG course.
    • Prior authorization may be required for BCG immunotherapy.

    Product and Disease Background

    Adstiladrin is a gene therapy delivered through a non-replicating adenovirus vector carrying the human interferon alfa-2b gene. The FDA-approved setting is treatment of adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

    Policy Definitions

    BCG-Unresponsive or Refractory
    Persistent or recurrent CISCIS alone or with recurrent Ta/T1 disease within 12 months after completion of adequate BCG therapy
    Recurrent high-grade diseaseRecurrent high-grade Ta/T1 disease within 6 months after completion of adequate BCG therapy
    Early T1 high-grade diseaseT1 high-grade disease at the first evaluation following an induction BCG course
    Adequate BCG Therapy
    Initial inductionAt least 5 of 6 doses of an initial induction course
    Maintenance optionAt least 2 of 3 doses of maintenance therapy
    Second-induction option

    Initial Therapy

    Initial Therapy

    Initial therapy requires all clinical criteria and any applicable dose-increase conditions.

    Initial Adstiladrin therapy

    • Qualifying NMIBC diagnosis: Diagnosis of NMIBC characterized as CIS only; Ta/T1 high-grade disease with concomitant CIS; or Ta/T1 high-grade disease without CIS (off-label).One of three diagnosis patterns

      The off-label presentation requires applicable evidence and policy review.

    • Clinical requirements: Prescribed by or in consultation with an oncologist or urologist; member is at least 18 years old; member is refractory to BCG treatment; and member is not a candidate for cystectomy.Age ≥18 years

      Prior authorization may be required for BCG immunotherapy.

    • Dose-increase condition when applicable

    Continuation Therapy

    Continuation Therapy

    Continued therapy is covered when all listed criteria are met.

    Continued Adstiladrin therapy

    • Current treatment status

      • Member is currently receiving medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Adstiladrin for a covered indication and has received the medication for at least 30 days.At least 30 days of current therapy
    • Positive response: Member is responding positively to therapy as evidenced by freedom from high-grade disease recurrence, evaluated by cytology, cystoscopy, and/or biopsy.No high-grade disease recurrence

    Required Prior Treatment

    StepRequirementAdequate BCG treatmentBCG-unresponsive or refractory disease
    1
    Member must be refractory to or BCG-unresponsive after adequate BCG treatment.
    At least 5 of 6 doses of an initial induction course plus either at least 2 of 3 maintenance doses or at least 2 of 6 doses of a second induction course.
    At least one of the following: persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months after adequate BCG therapy; recurrent high-grade Ta/T1 disease within 6 months after adequate BCG therapy; or T1 high-grade disease at the first evaluation after an induction BCG course.

    Quantity and Frequency Limits

    Adstiladrin Quantity Limits
    Maximum volume per course75 mL
    Maximum vial count4 vials
    Concentration3 × 10^11 vp/mL
    Treatment frequencyEvery 3 months
    Standard regimenInitial dose followed by retreatment at months 4, 7, and 10, for a total of four doses
    Policy Summary
    PayerAmbetter Nevada
    PolicyNadofaragene firadenovec-vncg (Adstiladrin) Coverage Policy
    Policy CodePolicy CP.PHAR.461
    Change TypeModified
    Effective DateDecember 1, 2022
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with clinical records supporting that all applicable approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing ParametersPrior Authorization and Provider RequirementsProduct and Disease BackgroundPolicy DefinitionsInitial TherapyContinuation TherapyRequired Prior TreatmentQuantity and Frequency Limits

    Requested use not specifically listed as unauthorized

    • The requested use, including diagnosis, age, or dosing regimen, is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
    • The recently changed-label pathway above does not apply.
    • Refer to the off-label use policy for the applicable line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
    Four total doses
    BCG Therapeutic Alternative Regimen
    TherapyBacillus Calmette-Guerin (BCG), live TICE BCG
    Intravesical dose1 to 8 × 10^8 CFU (one vial)
    ScheduleIntravesical instillation once per week for 6 weeks
    Documentation Required

    Initial-Therapy Support

    For initial therapy, submit documentation supporting the diagnosis and all required member and prescriber criteria.

    • Member is at least 18 years of age.
    • Diagnosis is CIS only; Ta/T1 high-grade disease with concomitant CIS; or Ta/T1 high-grade disease without CIS when supported as an off-label use.
    • Adstiladrin is prescribed by or in consultation with an oncologist or urologist.
    • Member is refractory to or BCG-unresponsive and is not a candidate for cystectomy.
    Documentation Required

    Clinical Records Required

    Submit clinical records that substantiate the requested therapy and demonstrate that all approval criteria are met.

    • Office chart notes, laboratory results, pathology, cytology, cystoscopy, biopsy results, and other relevant clinical information may be required.
    Documentation Required

    Dose-Increase Evidence

    When requesting a dose increase, provide evidence supporting the requested regimen if it relies on relevant off-label dosing.

    • Submit applicable practice guidelines or peer-reviewed literature supporting the dose and off-label use.
    • The prescribed regimen must be FDA-approved or recommended by NCCN.
    Documentation Required

    Continuation Records

    For continued therapy, document current Adstiladrin use and a positive response to treatment.

    • Member is receiving the medication through the Centene benefit, or documentation shows current Adstiladrin use for a covered indication for at least 30 days.
    • Document freedom from high-grade disease recurrence as evaluated by cytology, cystoscopy, and/or biopsy.
    Denial Risk

    Unauthorized Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient evidence supports the off-label use under the applicable policy or evidence of coverage document.

    • Refer to CP.CPA.09 for commercial plans, HIM.PA.154 for health insurance marketplace/ICHRA plans, or CP.PMN.53 for Medicaid, as applicable.
    Denial Risk

    Initial Criteria Not Met

    Initial therapy may be denied when the required clinical criteria are not met.

    • Member is younger than 18 years.
    • Requested diagnosis is not an authorized indication and lacks sufficient off-label support.
    • Member is not refractory to or BCG-unresponsive, or is a candidate for cystectomy.
    • Prescription is not from or in consultation with an oncologist or urologist.
    • The prescribed regimen is neither FDA-approved nor recommended by NCCN.
    Denial Risk

    Product Hypersensitivity

    Coverage is precluded when the member has hypersensitivity to interferon alfa or any component of Adstiladrin.

    • Review the product contraindication before submitting the request.
    Denial Risk

    Continuation Criteria Not Met

    Continued therapy may be denied when current-use and response requirements are not documented.

    • Member is not currently receiving Adstiladrin through the Centene benefit and qualifying current-use documentation is absent.
    • Current use for a covered indication has not continued for at least 30 days.
    • The member is not responding positively, including recurrence of high-grade disease or insufficient cytology, cystoscopy, or biopsy documentation.
    Denial Risk

    Dose Exceeds Policy Limit

    A requested dose above the policy limit requires supporting evidence or may be denied.

    • Standard maximum: 75 mL (4 vials) of 3 × 10^11 viral particles (vp)/mL every 3 months, with a total of four doses for high-grade BCG-unresponsive NMIBC.
    • For an increased dose above this limit, submit practice guidelines or peer-reviewed literature supporting the relevant off-label use.
    • The prescribed regimen must be FDA-approved or recommended by NCCN.
    At least 2 of 6 doses of a second induction course
    NMIBC, CIS, and Ta/T1
    NMIBCNon-muscle-invasive bladder cancer
    CISCarcinoma in situ
    Ta/T1Ta refers to papillary tumors; T1 tumors have grown into the connective tissue of the bladder wall but not into the muscle layer
    vp
    Abbreviationvp
    DefinitionViral particles
    Dosing contextUsed to express nadofaragene firadenovec concentration, such as vp/mL
    • Requested dose does not exceed 75 mL (4 vials) of 3 × 10^11 viral particles (vp)/mL every 3 months.
    • Requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

  1. Dose-increase condition when applicable

    • New dose does not exceed 75 mL (4 vials) of 3 × 10^11 vp/mL every 3 months.
    • New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.